Abstract
Asthma is a chronic inflammatory disorder of the respiratory system characterised by recurrent “reversible” obstruction of the airwflow in the airway. Various agents have been used in the treatment of asthma out of which inhaled beta-2 agonists have been mainstay of bronchodilator therapy of asthma for more than 40 years. Short-acting beta-2 agonists are still recommended for relieving the acute episode of bronchoconstriction. Long-acting beta-2 agonists (LABAs), alongwith inhaled corticosteroides are used as a first line anti-inflammatory therapy. The recent evidence suggested that the ability of short-acting and long-acting beta-2 agonists to protect the airways against bronchoconstrictor stimuli and to promote bronchodilatation may be partially lost with time following long-term use. The long-term use of beta-2 agonist is associated with an increased incidence of asthma exacerbations and other markers of morbidity and mortality. In this article, we try to address some of the current controversies as well as propose various mechanisms behind beta-2 agonist induced morbidity and mortality in asthmatic patients. On the basis of this article, we recommended that clinicians have to refine the use of beta-2 agonists in asthma management guidelines to avoid the beta-2 agonists induced asthma exacerbations.
Keywords: Asthma, long-acting beta-2 agonists, short-acting beta-2 agonists
Current Respiratory Medicine Reviews
Title: Beta-2 Agonists in Asthma: Medicine or Murderer?
Volume: 4 Issue: 3
Author(s): Vasanti Patel, Dipika Patel, Natvarbhai Patel and Priyanshee Gohil
Affiliation:
Keywords: Asthma, long-acting beta-2 agonists, short-acting beta-2 agonists
Abstract: Asthma is a chronic inflammatory disorder of the respiratory system characterised by recurrent “reversible” obstruction of the airwflow in the airway. Various agents have been used in the treatment of asthma out of which inhaled beta-2 agonists have been mainstay of bronchodilator therapy of asthma for more than 40 years. Short-acting beta-2 agonists are still recommended for relieving the acute episode of bronchoconstriction. Long-acting beta-2 agonists (LABAs), alongwith inhaled corticosteroides are used as a first line anti-inflammatory therapy. The recent evidence suggested that the ability of short-acting and long-acting beta-2 agonists to protect the airways against bronchoconstrictor stimuli and to promote bronchodilatation may be partially lost with time following long-term use. The long-term use of beta-2 agonist is associated with an increased incidence of asthma exacerbations and other markers of morbidity and mortality. In this article, we try to address some of the current controversies as well as propose various mechanisms behind beta-2 agonist induced morbidity and mortality in asthmatic patients. On the basis of this article, we recommended that clinicians have to refine the use of beta-2 agonists in asthma management guidelines to avoid the beta-2 agonists induced asthma exacerbations.
Export Options
About this article
Cite this article as:
Patel Vasanti, Patel Dipika, Patel Natvarbhai and Gohil Priyanshee, Beta-2 Agonists in Asthma: Medicine or Murderer?, Current Respiratory Medicine Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339808785161323
DOI https://dx.doi.org/10.2174/157339808785161323 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets A Fast and Simple Conductometric Method for Verapamil Hydrochloride Determination in Pharmaceutical Formulations
Current Pharmaceutical Analysis Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy
Current Vascular Pharmacology Building Mosaics of Therapeutic Plasmid Gene Vectors
Current Gene Therapy Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Challenges in Treatment of Inappropriate Sinus Tachycardia
Current Cardiology Reviews Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design